Latest Content

The antibiotic's approval was based from phase 3 results demonstrating noninferiority to a combination therapy.

Infectious disease pediatrician Sharon Nachman, MD, talks about how the new recommendations will defer immunization, leading to a whole host of issues and negative impacts on long-term public health.

GSK’s David Payne, PhD, provides more information are the data from the EAGLE-1 trial.

The federal nod was given based from the phase 3 data of the EAGLE-1 trial, which showed noninferiority to combination therapy. This approval provides a new oral option.

NYU’s Angelica Cifuentes Kottkamp, MD, continues our Media Day discussion around these illnesses and how in New York City, clinicians need to be prepared to decipher in differential diagnosis for these potential diseases.

Reports are surfacing the federal agency is going to review products already reviewed and approved.

In episode 2 of our Media Day series with New York University (NYU), Angelica Cifuentes Kottkamp, MD, discusses its vaccine center and their work around COVID-19 vaccines, as well as the importance of achieving diversity in clinical trials.

Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases, discusses the changes in the new vaccine recommendations and what potential serious consequences may be seen as a result.

The federal agency approved Augmentin XR in just 2 months through the new CNPV pilot program, marking a potential step toward rebuilding domestic antibiotic manufacturing and addressing drug shortages.

A large meta-analysis indicates opioid exposure may disrupt immunity and gut microbiota, increasing CDI vulnerability and potentially worsening clinical outcomes.

Angelica Cifuentes Kottkamp, MD, discusses how its location, breadth of experience, and opportunities afford clinicians the ability to see and treat a wide berth of diseases and infections.

Most clinical isolates identified as triazole-resistant Aspergillus niger by traditional clinical laboratory methods were revealed by DNA sequencing to be A tubingensis.

Population study corroborates 2019 FDA alert based on case reports of acute respiratory failure with TMP-SMX in healthy adolescents and young adults.